Search Results - "McCUNE, Jeannine S"

Rapid Advances in Immunotherapy to Treat Cancer by McCune, Jeannine S.

“…Immunotherapy is now the fourth pillar of cancer therapy, with surgery, radiation, and traditional chemotherapy being the remaining pillars. Over the past…”
Get full text

Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study by Bekaii-Saab, Tanios S, Prof, Ou, Fang-Shu, PhD, Ahn, Daniel H, DO, Boland, Patrick M, MD, Ciombor, Kristen K, MD, Heying, Erica N, BS, Dockter, Travis J, MS, Jacobs, Nisha L, MD, Pasche, Boris C, Prof, Cleary, James M, MD, Meyers, Jeffrey P, BS, Desnoyers, Rodwige J, MD, McCune, Jeannine S, Prof, Pedersen, Katrina, MD, Barzi, Afsaneh, MD, Chiorean, E Gabriela, Prof, Sloan, Jeffrey, Prof, Lacouture, Mario E, Prof, Lenz, Heinz-Josef, Prof, Grothey, Axel, MD

“…SummaryBackgroundRegorafenib confers an overall survival benefit in patients with refractory metastatic colorectal cancer; however, the adverse event profile…”
Get full text

Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation by Mielcarek, Marco, Furlong, Terry, O'Donnell, Paul V., Storer, Barry E., McCune, Jeannine S., Storb, Rainer, Carpenter, Paul A., Flowers, Mary E.D., Appelbaum, Frederick R., Martin, Paul J.

“…The cumulative incidence of National Institutes of Health (NIH)-defined chronic graft-versus-host disease (GVHD) requiring systemic treatment is ∼35% at 1 year…”
Get full text

A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer by Schweizer, Michael T, Haugk, Kathleen, McKiernan, Jožefa S, Gulati, Roman, Cheng, Heather H, Maes, Jessica L, Dumpit, Ruth F, Nelson, Peter S, Montgomery, Bruce, McCune, Jeannine S, Plymate, Stephen R, Yu, Evan Y

“…Niclosamide, an FDA-approved anti-helminthic drug, has activity in preclinical models of castration-resistant prostate cancer (CRPC). Potential mechanisms of…”
Get full text

Pharmacokinetics, Pharmacodynamics and Pharmacogenomics of Immunosuppressants in Allogeneic Haematopoietic Cell Transplantation: Part I by McCune, Jeannine S., Bemer, Meagan J.

“…Although immunosuppressive treatments and target concentration intervention (TCI) have significantly contributed to the success of allogeneic haematopoietic…”
Get full text

Busulfan in Infant to Adult Hematopoietic Cell Transplant Recipients: A Population Pharmacokinetic Model for Initial and Bayesian Dose Personalization by McCUNE, Jeannine S, BEMER, Meagan J, BARRETT, Jeffrey S, BAKER, K. Scott, GAMIS, Alan S, HOLFORD, Nicholas H. G

“…Personalizing intravenous busulfan doses to a target plasma concentration at steady state (Css) is an essential component of hematopoietic cell transplantation…”
Get full text

Pulsed High-Intensity Focused Ultrasound Enhances Delivery of Doxorubicin in a Preclinical Model of Pancreatic Cancer by Li, Tong, Wang, Yak-Nam, Khokhlova, Tatiana D, D'Andrea, Samantha, Starr, Frank, Chen, Hong, McCune, Jeannine S, Risler, Linda J, Mashadi-Hossein, Afshin, Hingorani, Sunil R, Chang, Amy, Hwang, Joo Ha

“…Pancreatic cancer is characterized by extensive stromal desmoplasia, which decreases blood perfusion and impedes chemotherapy delivery. Breaking the stromal…”
Get full text

Precision sirolimus dosing in children: The potential for model-informed dosing and novel drug monitoring by Shen, Guofang, Moua, Kao Tang Ying, Perkins, Kathryn, Johnson, Deron, Li, Arthur, Curtin, Peter, Gao, Wei, McCune, Jeannine S

“…The mTOR inhibitor sirolimus is prescribed to treat children with varying diseases, ranging from vascular anomalies to sporadic lymphangioleiomyomatosis to…”
Get full text

Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II by McCune, Jeannine S., Bemer, Meagan J., Long-Boyle, Janel

“…Part I of this article included a pertinent review of allogeneic hematopoietic cell transplantation (alloHCT), the role of postgraft immunosuppression in…”
Get full text

Haploidentical hematopoietic cell and kidney transplantation for hematological malignancies and end-stage renal failure by Chen, Yi-Bin, Elias, Nahel, Heher, Eliot, McCune, Jeannine S., Collier, Kerry, Li, Shuli, Del Rio, Candice, El-Jawahri, Areej, Williams, Winfred, Tolkoff-Rubin, Nina, Fishman, Jay A., McAfee, Steven, Dey, Bimalangshu R., DeFilipp, Zachariah, O'Donnell, Paul V., Cosimi, A. Benedict, Sachs, David, Kawai, Tatsuo, Spitzer, Thomas R.

“…At Massachusetts General Hospital, we pioneered simultaneous hematopoietic cell (HCT)/kidney transplantation from HLA-identical related donors for the…”
Get full text

The presence of busulfan metabolites and pharmacometabolomics in plasma drawn immediately before allograft infusion in hematopoietic cell transplant recipients by McCune, Jeannine S., Navarro, Sandi L., Risler, Linda J., Phillips, Brian R., Ren, Suping, Schoch, H. Gary, Baker, K. Scott

“…Busulfan is hepatically metabolized through glutathione (GSH) conjugation; in vitro, this process depletes hepatocyte GSH stores and generates the cytotoxic…”
Get full text

Challenges with sirolimus experimental data to inform QSP model of post‐transplantation cyclophosphamide regimens by Mohanan, Ezhilpavai, Shen, Guofang, Ren, Suping, Fan, Hsuan‐Hao, Moua, Kao Tang Ying, Karolak, Aleksandra, Rockne, Russell C., Nakamura, Ryotaro, Horne, David A., Kanakry, Christopher G., Mager, Donald E., McCune, Jeannine S.

“…Dose optimization of sirolimus may further improve outcomes in allogeneic hematopoietic cell transplant (HCT) patients receiving post‐transplantation…”
Get full text

Lipidomics of cyclophosphamide 4‐hydroxylation in patients receiving post‐transplant cyclophosphamide by Navarro, Sandi L., Zheng, Zihan, Randolph, Timothy W., Nakamura, Ryotaro, Sandmaier, Brenda M., Hockenbery, David, McCune, Jeannine S.

“…Biomarker‐guided dosing may improve the efficacy and toxicity of cyclophosphamide (CY); however, clinical studies evaluating their association with the area…”
Get full text

Pharmacometabonomic association of cyclophosphamide 4‐hydroxylation in hematopoietic cell transplant recipients by McCune, Jeannine S., Nakamura, Ryotaro, O’Meally, Denis, Randolph, Timothy W., Sandmaier, Brenda M., Karolak, Aleksandra, Hockenbery, David, Navarro, Sandi L.

“…The widely used alkylating agent cyclophosphamide (CY) has substantive interpatient variability in the area under the curve (AUC) of it and its metabolites…”
Get full text

Adapting regulatory drug‐drug interaction guidance to design clinical pharmacokinetic natural product‐drug interaction studies: A NaPDI Center recommended approach by Cox, Emily J., Rettie, Allan E., Unadkat, Jashvant D., Thummel, Kenneth E., McCune, Jeannine S., Paine, Mary F.

“…Pharmacokinetic drug interactions precipitated by botanical and other natural products (NPs) remain critically understudied. Investigating these complex…”
Get full text

Abnormal body composition is a predictor of adverse outcomes after autologous haematopoietic cell transplantation by Armenian, Saro H., Iukuridze, Aleksi, Teh, Jennifer Berano, Mascarenhas, Kristen, Herrera, Alex, McCune, Jeannine S., Zain, Jasmine M., Mostoufi‐Moab, Sogol, McCormack, Shana, Slavin, Thomas P., Scott, Jessica M., Jones, Lee W., Sun, Can‐Lan, Forman, Stephen J., Wong, F. Lennie, Nakamura, Ryotaro

“…Background The number of patients undergoing autologous haematopoietic cell transplant (HCT) is growing, but little is known about the factors that predict…”
Get full text

Co‐consuming green tea with raloxifene decreases raloxifene systemic exposure in healthy adult participants by Clarke, John D., Judson, Sabrina M., Tian, Dan‐Dan, Kirby, Trevor O., Tanna, Rakshit S., Matula‐Péntek, Adrienn, Horváth, Miklós, Layton, Matthew E., White, John R., Cech, Nadja B., Thummel, Kenneth E., McCune, Jeannine S., Shen, Danny D., Paine, Mary F.

“…Abstract Green tea is a popular beverage worldwide. The abundant green tea catechin (−)‐epigallocatechin gallate (EGCG) is a potent in vitro inhibitor of…”
Get full text

Metformin and Chemoprevention: Potential for Heart-Healthy Targeting of Biologically Aggressive Breast Cancer by Jones, Veronica C, Dietze, Eric C, Jovanovic-Talisman, Tijana, McCune, Jeannine S, Seewaldt, Victoria L

“…Currently, tamoxifen is the only drug approved for reduction of breast cancer risk in premenopausal women. The significant cardiovascular side effects of…”
Get full text

Optimal Prevention of Seizures Induced by High-Dose Busulfan by Eberly, Andrea L., Anderson, Gail D., Bubalo, Joseph S., McCune, Jeannine S.

“…High‐dose busulfan is frequently used in a variety of conditioning regimens for hematopoietic cell transplantation. In this setting, busulfan has marked…”
Get full text

Correction: A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer by Schweizer, Michael T, Haugk, Kathleen, McKiernan, Jožefa S, Gulati, Roman, Cheng, Heather H, Maes, Jessica L, Dumpit, Ruth F, Nelson, Peter S, Montgomery, Bruce, McCune, Jeannine S, Plymate, Stephen R, Yu, Evan Y

“…[This corrects the article DOI: 10.1371/journal.pone.0198389.]…”
Get full text